STOCK TITAN

Akero Therapeutics, Inc. - $AKRO STOCK NEWS

Welcome to our dedicated page for Akero Therapeutics news (Ticker: $AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akero Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akero Therapeutics's position in the market.

Rhea-AI Summary
Akero Therapeutics collects all samples and data for Phase 2b SYMMETRY study, with topline results expected in October. Results will include histology, fibrosis measures, glycemic control, lipoproteins, safety, and tolerability. Investor webcast planned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
conferences clinical trial
-
Rhea-AI Summary
Akero Therapeutics (AKRO) reported positive results from Phase 2b SYMMETRY Cohort D, expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist. Phase 3 SYNCHRONY studies on track to begin enrolling in the second half of 2023. $334.8 million in net proceeds raised. Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended June 30, 2023 were $658.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
Akero Therapeutics, Inc.

Nasdaq:AKRO

AKRO Rankings

AKRO Stock Data

1.36B
46.04M
5.77%
92.13%
11.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About AKRO

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.